Lenvatinib Phase II Results Show Significant Improvement in Progression-Free Survival When Used With Everolimus

Phase II results show lenvatinib, when used in combination with everolimus, demonstrates significantly improved progression-free survival (PFS) versus everolimus alone in people with metastatic renal cell carcinoma (mRCC) following prior VEGF-targeted therapy.10/16/2015
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news